We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+3.29%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$43.8B
AUM Growth
+$2.95B
(+7.2%)
Cap. Flow
+$2.92B
Cap. Flow
% of AUM
6.68%
Top 10 Holdings %
Top 10 Hldgs %
29.71%
Holding
2,321
New
255
Increased
1,689
Reduced
325
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$408M |
| 2 |
NVIDIA
NVDA
|
+$395M |
| 3 |
Microsoft
MSFT
|
+$382M |
| 4 |
Amazon
AMZN
|
+$253M |
| 5 |
Palantir
PLTR
|
+$148M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walmart Inc
WMT
|
+$285M |
| 2 |
NextEra Energy
NEE
|
+$207M |
| 3 |
West Pharmaceutical
WST
|
+$168M |
| 4 |
Broadcom
AVGO
|
+$133M |
| 5 |
Meta Platforms (Facebook)
META
|
+$128M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.42% |
| 2 | Consumer Discretionary | 10.78% |
| 3 | Consumer Staples | 10.15% |
| 4 | Industrials | 10.05% |
| 5 | Financials | 9.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2176
Cardiff Oncology
CRDF
$64.3M
| $49.9K | ﹤0.01% |
+11,486
| New | +$35.9K |
|
2177
Sutro Biopharma
STRO
$379M
| $49.6K | ﹤0.01% |
2,696
+1,149
| +74% | +$35.1K |
|
|
INZY
2178
DELISTED
Inozyme Pharma
INZY
| $49.3K | ﹤0.01% |
+17,807
| New | +$67.7K |
|
2179
Zentalis Pharmaceuticals
ZNTL
$308M
| $48.8K | ﹤0.01% |
16,094
-13,904
| -46% | -$45.6K |
|
2180
Perspective Therapeutics
CATX
$332M
| $48.6K | ﹤0.01% |
15,225
+5,011
| +49% | +$40.9K |
|
|
SCPH
2181
DELISTED
scPharmaceuticals
SCPH
| $47.7K | ﹤0.01% |
+13,465
| New | +$51.6K |
|
|
TSVT
2182
DELISTED
2seventy bio
TSVT
| $47.6K | ﹤0.01% |
+16,206
| New | +$66.5K |
|
2183
BRC Inc
BRCC
$126M
| $47.2K | ﹤0.01% |
+14,886
| New | +$46.5K |
|
|
MPT
2184
Medical Properties Trust
MPT
$2.89B
| $46.8K | ﹤0.01% |
11,851
+56
| +0.5% | +$251 |
|
2185
Nektar Therapeutics
NKTR
$2.39B
| $46.8K | ﹤0.01% |
3,352
+1,103
| +49% | +$19.5K |
|
2186
Acacia Research
ACTG
$450M
| $46.1K | ﹤0.01% |
+10,633
| New | +$48.2K |
|
2187
PLAYSTUDIOS Inc
MYPS
$79.3M
| $46.1K | ﹤0.01% |
24,793
+8,159
| +49% | +$14K |
|
2188
W&T Offshore
WTI
$545M
| $46.1K | ﹤0.01% |
27,779
-9,493
| -25% | -$19K |
|
2189
Digital Turbine
APPS
$1.02B
| $45.7K | ﹤0.01% |
27,024
+8,892
| +49% | +$19.8K |
|
2190
Chegg
CHGG
$108M
| $45.7K | ﹤0.01% |
28,360
+9,600
| +51% | +$17.7K |
|
2191
ADC Therapeutics
ADCT
$146M
| $45.6K | ﹤0.01% |
22,901
+7,535
| +49% | +$19.7K |
|
2192
Nkarta
NKTX
$162M
| $45.4K | ﹤0.01% |
+18,244
| New | +$56.3K |
|
2193
Nokia
NOK
$50.8B
| $45.3K | ﹤0.01% |
10,226
-4,903
| -32% | -$21.9K |
|
2194
Dakota Gold
DC
$623M
| $43.4K | ﹤0.01% |
19,735
+6,965
| +55% | +$15.7K |
|
2195
Cardlytics
CDLX
$21M
| $43.4K | ﹤0.01% |
+1,170
| New | +$44.8K |
|
|
IAUX
2196
i-80 Gold Corp
IAUX
$1.17B
| $43.2K | ﹤0.01% |
89,168
+29,339
| +49% | +$23.7K |
|
2197
Coherus Oncology
CHRS
$217M
| $43.2K | ﹤0.01% |
31,335
+3,504
| +13% | +$3.93K |
|
2198
LanzaTech
LNZA
$61.3M
| $43.1K | ﹤0.01% |
315
+104
| +49% | +$15.6K |
|
2199
NN Inc
NNBR
$272M
| $42.8K | ﹤0.01% |
+13,102
| New | +$50K |
|
2200
Rackspace Technology
RXT
$1B
| $42.1K | ﹤0.01% |
19,030
+6,398
| +51% | +$16.1K |
|
Similar funds
ProShare Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, ProShare Advisors held 2,321 positions worth $43.8B, up 7.2% from $40.8B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
ProShare Advisors deployed $2.92B of net new capital in Q4 2024, opening 255 new positions and adding to 1,689 existing holdings. Its largest new stake was Applovin: 338,942 shares worth $110M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 29% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Walmart Inc, an estimated $285M trimmed.
- ProShare Advisors's largest Q4 2024 buy was Applovin: 338,942 shares worth $110M.
- ProShare Advisors added most to Apple in Q4 2024, an estimated $408M increase.
- ProShare Advisors's biggest Q4 2024 reduction was Walmart Inc, cutting an estimated $285M.
- ProShare Advisors fully exited PetIQ, Inc. Class A Common Stock in Q4 2024, selling an estimated $3.25M.
- ProShare Advisors's ten largest holdings make up 30% of its $43.8B portfolio in Q4 2024.
- ProShare Advisors opened 255 new positions and closed 50 in Q4 2024.
- ProShare Advisors's portfolio value rose 7.2% quarter-over-quarter to $43.8B.
Based on ProShare Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.